News & Updates

Show Multimedia Only
COVID-19 variants carry no increased autoimmune sequelae risk

COVID-19 variants carry no increased autoimmune sequelae risk

16 Sep 2024 byJairia Dela Cruz

COVID-19 variants delta and omicron BA.1 or BA.2 do not pose a substantial threat of long-term autoimmune complications, except for a modest elevation in inflammatory bowel disease and bullous skin disorders among hospitalized patients during the omicron predominance in Singapore, as shown in a study.

COVID-19 variants carry no increased autoimmune sequelae risk

16 Sep 2024
Cruciferous vegetables help avert recurrence in NMIBC patients on BCG

Cruciferous vegetables help avert recurrence in NMIBC patients on BCG

16 Sep 2024
No benefit to SGLT2 inhibitor therapy in hospitalized COVID-19 patients

No benefit to SGLT2 inhibitor therapy in hospitalized COVID-19 patients

15 Sep 2024
Enzalutamide edges out abiraterone in mCRPC

Enzalutamide edges out abiraterone in mCRPC

15 Sep 2024 byJairia Dela Cruz

In the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), the use of enzalutamide yields small improvements in outcomes when compared with abiraterone acetate, according to a retrospective study.

Enzalutamide edges out abiraterone in mCRPC

15 Sep 2024